CA Patent

CA3175856A1 — Pharmaceutical formulations and uses thereof

Assigned to Aldeyra Therapeutics Inc · Expires 2021-11-18 · 4y expired

What this patent protects

The present invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof, which are useful for treatment of a disease, disorder, or condition such as inflammatory diseases, respiratory diseas…

USPTO Abstract

The present invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof, which are useful for treatment of a disease, disorder, or condition such as inflammatory diseases, respiratory diseases, organ diseases, viral infections, and sequelae and associated conditions such as acute respiratory distress sydrome.

Drugs covered by this patent

Patent Metadata

Patent number
CA3175856A1
Jurisdiction
CA
Classification
Expires
2021-11-18
Drug substance claim
No
Drug product claim
No
Assignee
Aldeyra Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.